vs
Arcturus Therapeutics Holdings Inc.（ARCT）与Digimarc CORP（DMRC）财务数据对比。点击上方公司名可切换其他公司
Digimarc CORP的季度营收约是Arcturus Therapeutics Holdings Inc.的1.2倍（$8.9M vs $7.2M），Digimarc CORP同比增速更快（2.9% vs -68.4%），Digimarc CORP自由现金流更多（$895.0K vs $-74.5M），过去两年Digimarc CORP的营收复合增速更高（-5.3% vs -56.5%）
Arcturus Therapeutics Holdings Inc.是一家专注于RNA药物研发的美国生物科技企业，核心业务覆盖罕见病与传染病领域药物的研发、开发与商业化。该公司自主研发了专属脂质纳米颗粒递送技术，可用于递送小干扰RNA、信使RNA、基因编辑RNA、DNA、反义寡核苷酸、微小RNA等多种核酸药物。
迪吉马克公司是一家企业软件与服务提供商，其主打产品包含带数字标识符的软件，主要用于解决防伪问题、验证产品真伪、提升回收准确性以及实现供应链可追溯，产品可广泛应用于服装、快消品、美妆健康、汽车等多个行业领域。
ARCT vs DMRC — 直观对比
营收规模更大
DMRC
是对方的1.2倍
$7.2M
营收增速更快
DMRC
高出71.3%
-68.4%
自由现金流更多
DMRC
多$75.4M
$-74.5M
两年增速更快
DMRC
近两年复合增速
-56.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $7.2M | $8.9M |
| 净利润 | — | $-4.2M |
| 毛利率 | — | 63.5% |
| 营业利润率 | — | -48.2% |
| 净利率 | — | -47.2% |
| 营收同比 | -68.4% | 2.9% |
| 净利润同比 | 3.1% | 51.4% |
| 每股收益（稀释后） | — | $-0.18 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ARCTDMRC
| Q4 25 | $7.2M | $8.9M | ||
| Q3 25 | $17.2M | $7.6M | ||
| Q2 25 | $28.3M | $8.0M | ||
| Q1 25 | $29.4M | $9.4M | ||
| Q4 24 | $22.8M | $8.7M | ||
| Q3 24 | $41.7M | $9.4M | ||
| Q2 24 | $49.9M | $10.4M | ||
| Q1 24 | $38.0M | $9.9M |
净利润ARCTDMRC
| Q4 25 | — | $-4.2M | ||
| Q3 25 | $-13.4M | $-8.2M | ||
| Q2 25 | $-9.2M | $-8.2M | ||
| Q1 25 | $-14.1M | $-11.7M | ||
| Q4 24 | $-30.0M | $-8.6M | ||
| Q3 24 | $-6.9M | $-10.8M | ||
| Q2 24 | $-17.2M | $-9.3M | ||
| Q1 24 | $-26.8M | $-10.3M |
毛利率ARCTDMRC
| Q4 25 | — | 63.5% | ||
| Q3 25 | — | 58.3% | ||
| Q2 25 | — | 58.8% | ||
| Q1 25 | — | 65.0% | ||
| Q4 24 | — | 60.8% | ||
| Q3 24 | — | 62.4% | ||
| Q2 24 | — | 66.1% | ||
| Q1 24 | — | 62.5% |
营业利润率ARCTDMRC
| Q4 25 | — | -48.2% | ||
| Q3 25 | -96.3% | -109.7% | ||
| Q2 25 | -41.0% | -105.2% | ||
| Q1 25 | -57.3% | -128.9% | ||
| Q4 24 | -146.7% | -105.1% | ||
| Q3 24 | -25.8% | -120.4% | ||
| Q2 24 | -42.4% | -96.2% | ||
| Q1 24 | -80.0% | -109.2% |
净利率ARCTDMRC
| Q4 25 | — | -47.2% | ||
| Q3 25 | -78.4% | -106.9% | ||
| Q2 25 | -32.4% | -102.6% | ||
| Q1 25 | -47.9% | -125.2% | ||
| Q4 24 | -131.8% | -99.9% | ||
| Q3 24 | -16.6% | -113.9% | ||
| Q2 24 | -34.5% | -89.3% | ||
| Q1 24 | -70.5% | -104.0% |
每股收益（稀释后）ARCTDMRC
| Q4 25 | — | $-0.18 | ||
| Q3 25 | $-0.49 | $-0.38 | ||
| Q2 25 | $-0.34 | $-0.38 | ||
| Q1 25 | $-0.52 | $-0.55 | ||
| Q4 24 | $-1.10 | $-0.40 | ||
| Q3 24 | $-0.26 | $-0.50 | ||
| Q2 24 | $-0.64 | $-0.43 | ||
| Q1 24 | $-1.00 | $-0.50 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $230.9M | $12.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $214.0M | $40.2M |
| 总资产 | $271.1M | $53.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ARCTDMRC
| Q4 25 | $230.9M | $12.9M | ||
| Q3 25 | $180.4M | $12.6M | ||
| Q2 25 | $196.5M | $16.1M | ||
| Q1 25 | $216.9M | $21.6M | ||
| Q4 24 | $237.0M | $28.7M | ||
| Q3 24 | $237.2M | $33.7M | ||
| Q2 24 | $260.3M | $41.5M | ||
| Q1 24 | $288.4M | $48.9M |
股东权益ARCTDMRC
| Q4 25 | $214.0M | $40.2M | ||
| Q3 25 | $224.6M | $41.4M | ||
| Q2 25 | $231.1M | $46.5M | ||
| Q1 25 | $233.8M | $50.0M | ||
| Q4 24 | $241.0M | $61.4M | ||
| Q3 24 | $261.9M | $70.2M | ||
| Q2 24 | $258.6M | $77.2M | ||
| Q1 24 | $264.0M | $84.5M |
总资产ARCTDMRC
| Q4 25 | $271.1M | $53.0M | ||
| Q3 25 | $282.3M | $55.4M | ||
| Q2 25 | $309.3M | $60.7M | ||
| Q1 25 | $331.8M | $66.5M | ||
| Q4 24 | $344.1M | $75.8M | ||
| Q3 24 | $370.7M | $85.0M | ||
| Q2 24 | $388.6M | $93.4M | ||
| Q1 24 | $418.8M | $99.7M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-74.3M | $991.0K |
| 自由现金流经营现金流 - 资本支出 | $-74.5M | $895.0K |
| 自由现金流率自由现金流/营收 | -1035.2% | 10.0% |
| 资本支出强度资本支出/营收 | 3.2% | 1.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-12.3M |
8季度趋势，按日历期对齐
经营现金流ARCTDMRC
| Q4 25 | $-74.3M | $991.0K | ||
| Q3 25 | $-17.2M | $-2.6M | ||
| Q2 25 | $-5.8M | $-4.7M | ||
| Q1 25 | $-35.1M | $-5.5M | ||
| Q4 24 | $-284.0K | $-4.2M | ||
| Q3 24 | $-23.8M | $-7.1M | ||
| Q2 24 | $-30.1M | $-6.8M | ||
| Q1 24 | $-5.6M | $-8.4M |
自由现金流ARCTDMRC
| Q4 25 | $-74.5M | $895.0K | ||
| Q3 25 | $-17.3M | $-2.8M | ||
| Q2 25 | — | $-4.9M | ||
| Q1 25 | $-35.3M | $-5.5M | ||
| Q4 24 | — | $-4.2M | ||
| Q3 24 | $-23.8M | $-7.2M | ||
| Q2 24 | $-30.5M | $-6.9M | ||
| Q1 24 | $-5.8M | $-8.5M |
自由现金流率ARCTDMRC
| Q4 25 | -1035.2% | 10.0% | ||
| Q3 25 | -101.1% | -36.9% | ||
| Q2 25 | — | -61.0% | ||
| Q1 25 | -120.1% | -59.1% | ||
| Q4 24 | — | -49.1% | ||
| Q3 24 | -57.2% | -75.7% | ||
| Q2 24 | -61.1% | -66.1% | ||
| Q1 24 | -15.3% | -85.8% |
资本支出强度ARCTDMRC
| Q4 25 | 3.2% | 1.1% | ||
| Q3 25 | 1.1% | 2.9% | ||
| Q2 25 | 0.0% | 2.5% | ||
| Q1 25 | 0.5% | 0.6% | ||
| Q4 24 | 0.0% | 0.2% | ||
| Q3 24 | 0.2% | 0.7% | ||
| Q2 24 | 0.7% | 0.3% | ||
| Q1 24 | 0.6% | 1.1% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ARCT
暂无分部数据
DMRC
| Subscription | $5.3M | 60% |
| The Government | $3.6M | 41% |
